Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Boehringer Ingelheim's Jascayd Expands Reach in Rare Lung Diseases with New FDA Approval

Boehringer Ingelheim's Jascayd Expands Reach in Rare Lung Diseases with New FDA Approval

Boehringer Ingelheim has secured a significant expansion for its rare lung disease medication Jascayd, receiving FDA approval for the treatment of progressive pulmonary fibrosis (PPF). This latest development comes just two months after the drug's initial approval for idiopathic pulmonary fibrosis (IPF), marking a rapid advancement in the company's respiratory disease portfolio.

NoahAI News12/23/2025
Abbott's Volt PFA System Gains FDA Approval, Joining Competitive Cardiac Ablation Market

Abbott's Volt PFA System Gains FDA Approval, Joining Competitive Cardiac Ablation Market

Abbott has received Food and Drug Administration (FDA) approval for its Volt pulsed field ablation (PFA) system, marking a significant entry into the rapidly growing market for advanced cardiac arrhythmia treatments. The approval allows Abbott to compete with established players such as Medtronic, Boston Scientific, and Johnson & Johnson in the United States.

NoahAI News12/23/2025
BioMarin Discontinues Liver Disease Candidate Amid $4.8B Amicus Acquisition

BioMarin Discontinues Liver Disease Candidate Amid $4.8B Amicus Acquisition

BioMarin Pharmaceutical, a prominent player in the rare disease treatment space, has quietly discontinued development of BMN 349, an oral small molecule candidate for Alpha-1 antitrypsin deficiency (AATD)-associated liver disease. This strategic decision was revealed in a Securities and Exchange Commission filing on December 22, 2025, coinciding with the company's announcement of its $4.8 billion acquisition of Amicus Therapeutics.

NoahAI News12/23/2025
Abbott Receives Clearance for Heart Delivery Device in Premature Babies

Abbott Receives Clearance for Heart Delivery Device in Premature Babies

Abbott has announced regulatory clearance for a new device designed to treat patent ductus arteriosus (PDA), a life-threatening heart condition in premature infants. The Amplatzer Piccolo Delivery System, which has received both FDA clearance and CE mark, is set to improve the safety and ease of PDA closure procedures in the United States and European Union.

NoahAI News12/23/2025
Gilead Sciences Expands Antiviral Portfolio with $35M Deal for HSV Assets from Assembly Biosciences

Gilead Sciences Expands Antiviral Portfolio with $35M Deal for HSV Assets from Assembly Biosciences

Gilead Sciences has taken a significant step in bolstering its antiviral pipeline by exercising its option to license two promising herpes simplex virus (HSV) assets from Assembly Biosciences. The move, announced on December 22, 2025, marks the first tangible outcome of a strategic partnership formed between the two companies in October 2023.

NoahAI News12/23/2025
Shionogi to Acquire Tanabe Pharma's ALS Franchise in $2.5 Billion Deal

Shionogi to Acquire Tanabe Pharma's ALS Franchise in $2.5 Billion Deal

In a significant move that underscores the ongoing consolidation in the pharmaceutical industry, Japanese drugmaker Shionogi has announced plans to acquire Tanabe Pharma's amyotrophic lateral sclerosis (ALS) franchise for $2.5 billion. The deal, expected to close on or after April 1, will transfer ownership of the oral suspension Radicava ORS and its intravenous predecessor, along with related commercial capabilities.

NoahAI News12/23/2025
Roche's Lunsumio Gains FDA Approval for Subcutaneous Formulation, Enhancing Treatment Options in Follicular Lymphoma

Roche's Lunsumio Gains FDA Approval for Subcutaneous Formulation, Enhancing Treatment Options in Follicular Lymphoma

Roche's Genentech unit announced on Monday that the U.S. Food and Drug Administration (FDA) has approved Lunsumio Velo, a subcutaneous formulation of the blood cancer drug Lunsumio, for the treatment of follicular lymphoma in patients who have received two or more lines of systemic therapy. This approval marks a significant advancement in the administration of CD20xCD3 bispecific antibodies, offering patients a more convenient treatment option.

NoahAI News12/23/2025
Boehringer Ingelheim Expands Chronic Kidney Disease Portfolio with $448M Rectify Pharmaceuticals Deal

Boehringer Ingelheim Expands Chronic Kidney Disease Portfolio with $448M Rectify Pharmaceuticals Deal

Boehringer Ingelheim has made a significant move in its chronic kidney disease (CKD) strategy, partnering with Rectify Pharmaceuticals in a deal worth up to $448 million. The collaboration focuses on developing small molecules that enhance ABCC6 protein function, targeting vascular calcification in CKD patients.

NoahAI News12/23/2025
Incog BioPharma to Invest $200M in Indiana Sterile Injectables Facility Expansion

Incog BioPharma to Invest $200M in Indiana Sterile Injectables Facility Expansion

Incog BioPharma, a contract development and manufacturing organization (CDMO) specializing in sterile injectables, has announced plans for a significant expansion of its Fishers, Indiana manufacturing site. The company will invest approximately $200 million to boost production capacity, with the project expected to create around 1,000 new jobs by 2030.

NoahAI News12/23/2025
Samsung Biologics Expands to US with $280M Acquisition of GSK Manufacturing Site

Samsung Biologics Expands to US with $280M Acquisition of GSK Manufacturing Site

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), has made a significant move into the US market by acquiring GlaxoSmithKline's (GSK) Human Genome Sciences manufacturing facilities in Rockville, Maryland. The $280 million deal marks Samsung Biologics' first production site in the United States and represents a major step in the company's global expansion strategy.

NoahAI News12/23/2025
Medtronic's Diabetes Spinoff MiniMed Files for IPO, Faces Manufacturing Challenges

Medtronic's Diabetes Spinoff MiniMed Files for IPO, Faces Manufacturing Challenges

Medtronic's planned diabetes device spinoff, MiniMed, has filed for an initial public offering (IPO), marking a significant development in the competitive diabetes technology market. The company, which offers a comprehensive portfolio of insulin pumps, continuous glucose monitors (CGMs), and other diabetes management devices, aims to position itself as a unique player in the industry. However, the IPO filing has revealed both promising strategies and notable challenges for the new entity.

NoahAI News12/23/2025
China Biotech Deals Surge in Value Despite Geopolitical Tensions

China Biotech Deals Surge in Value Despite Geopolitical Tensions

In a year marked by geopolitical pressures and trade tensions, China's biotech sector has shown remarkable resilience, with deal values soaring to unprecedented heights. Despite concerns over national security and warnings about the United States' waning biotech innovation edge, China continues to be a prominent source of innovation for the global life sciences industry.

NoahAI News12/23/2025
«1...345...67»